'For the quarter ending March 2024, standalone Net sales (including other operating income) of RPG Life Sciences has increased 7.17% to Rs 126.99 crore compared to quarter ended March 2023.  Operating profit margin has jumped from 13.43% to 16.32%, leading to 30.23% rise in operating profit to Rs 20.72 crore.  Raw material cost as a % of total sales (net of stock adjustments) increased from 18.43% to 21.81%.   Purchase of finished goods cost fell from 16.65% to 11.61%.   Employee cost decreased from 27.75% to 24.96%.   Other expenses rose from 24.10% to 25.49%.   

Other income fell 10.33% to Rs 1.65 crore.  PBIDT rose 26.03% to Rs 22.37 crore.  Provision for interest up 180% to Rs 0.14 crore.  Loan funds remained nil.  Inventories rose to Rs 101.00 crore as of 31 March 2024 from Rs 95.05 crore as of 31 March 2023.  Sundry debtors were higher at Rs 49.13 crore as o...

• 

  (28-Feb-2026)

  Vesuvius India

  Net jumps 33% on higher OI
• 

  (26-Feb-2026)

  Foseco India

  Net down 35% on higher EO Exp
• 

  (26-Feb-2026)

  KSB

  Net up 11%, sales up 8%
• 

  (26-Feb-2026)

  Sanofi India

  OP down 23.67%